Ark enrolls first patient in Ph III Trinam trial

UK-based Ark Therapeutics has enrolled the first patient in its Phase III study of Trinam, a novel, gene-based medicine to prevent blood  vessels from blocking in kidney dialysis patients who have undergone  vascular access graft surgery.

The multicenter, randomized, controlled trial will test the efficacy and  safety of Trinam in patients with end-stage renal disease who require  vascular access for hemodialysis.

The results of a Phase II, open-label, non-randomized, standard-care  controlled trial, reported in 2007, showed that Trinam remained  functional for dialysis up to three times longer than control and the  product was well tolerated.